Daiichi Sankyo, Inc. Shifts 6 Early Drug Programs to India

Rediff -- Daiichi Sankyo, Japan's third-largest drug maker, has transferred six of its early drug discovery programmes in inflammatory and infectious diseases from its Japanese research & development (R&D) facilities to India.
MORE ON THIS TOPIC